Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants Ken OgasawaraJeanelle KamGopal Krishna Original Article 21 May 2021 Pages: 369 - 377
Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation Rachael LawsonLachlan PatersonStefanie Hennig Original Article 22 May 2021 Pages: 379 - 391
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers Masanobu TakahashiYasuhiro SakamotoChikashi Ishioka Original Article Open access 24 May 2021 Pages: 393 - 402
Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma Yun LiuBo ZhangJing Huang Original Article 24 May 2021 Pages: 403 - 414
A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis Pawat PattarawatJessica T. HuntHwa-Chain Robert Wang Original Article 27 May 2021 Pages: 415 - 425
Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study Lauriane GoldwirtB. LouveauS. Mourah Original Article 31 May 2021 Pages: 427 - 437
Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients Anna P. SokolenkoTatiana V. GorodnovaEvgeny N. Imyanitov Original Article 02 June 2021 Pages: 439 - 450
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors Venkatesh Pilla Reddy Adrian J. FretlandJoseph A. Ware Original Article Open access 02 June 2021 Pages: 451 - 464
A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers Xiaoxue ZhuHongjie QianXiaojiao Li Original Article Open access 04 June 2021 Pages: 465 - 474
Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability Li ChenCiao-Sin ChenDaniel L. Hertz Original Article 05 June 2021 Pages: 475 - 483
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment Muhammad Wasif SaifCarlos R. BecerraLee Rosen Original Article 07 June 2021 Pages: 485 - 497
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study Bei WangRong DengWhitney P. Kirschbrown Original Article Open access 09 June 2021 Pages: 499 - 512
Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression Kazuhisa SugiuHiroshi TazawaToshiyoshi Fujiwara Original Article 10 June 2021 Pages: 513 - 524
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer Motohiro FujiwaraTakeshi YuasaJunji Yonese Original Article 10 June 2021 Pages: 525 - 531
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients Nuala HelsbyMinghan YongDavid Porter Original Article 10 June 2021 Pages: 533 - 542
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure Ayako TsuboyaYutaro KubotaKen-ichi Fujita Original Article 11 June 2021 Pages: 543 - 553
Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model Morgan J. HomanAndrea FransonBernard L. Marini Short Communication 11 June 2021 Pages: 555 - 562
Correction to: PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1 Shuo YuYang LiLan Yang Correction 15 April 2021 Pages: 563 - 563